Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 3067-3075

  Chang, Jae H ^a   Plise, Emile ^a   Cheong, Jonathan ^a   Ho, Quynh ^a   Lin, Molly ^a  

^a GENENTECH INC   (United States)

Author keywords

bilirubin; BSEP; hypebilirubinemia; MRP2; OAT1B3; OATP1B1; UGT1A1

Indexed keywords

AMINOTRANSFERASE; ATAZANAVIR; BILE SALT EXPORTER PUMP; BROMFENAC; CARRIER PROTEIN; ESTRADIOL 3 GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 2; NELFINAVIR; PITAVASTATIN; PROTEIN OATP1B1; PROTEIN OATP1B3; RITONAVIR; TROGLITAZONE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INDUCED DISEASE; DRUG TRANSPORT; HUMAN; HYPERBILIRUBINEMIA; IC 50; IN VITRO STUDY; IONIZATION; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA PROTEIN BINDING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION;

BILIRUBIN; CELL LINE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; INDINAVIR; MODELS, BIOLOGICAL; OLIGOPEPTIDES; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIDINES;

EID: 84881338117     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4001348     Document Type: Article

References (60)

1. Tenhunen, R.; Marver, H. S.; Schmid, R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase Proc. Natl. Acad. Sci. U.S.A. 1968, 61 (2) 748-55
2. Cui, Y.; Konig, J.; Leier, I.; Buchholz, U.; Keppler, D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6 J. Biol. Chem. 2001, 276 (13) 9626-30
3. Scharschmidt, B. F.; Waggoner, J. G.; Berk, P. D. Hepatic organic anion uptake in the rat J. Clin. Invest. 1975, 56 (5) 1280-92
4. Bosma, P. J.; Seppen, J.; Goldhoorn, B.; Bakker, C.; Oude Elferink, R. P.; Chowdhury, J. R.; Chowdhury, N. R.; Jansen, P. L. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man J. Biol. Chem. 1994, 269 (27) 17960-4
5. Jedlitschky, G.; Leier, I.; Buchholz, U.; Hummel-Eisenbeiss, J.; Burchell, B.; Keppler, D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2 Biochem. J. 1997, 327 (Pt 1) 305-10
6. Keppler, D.; Kamisako, T.; Leier, I.; Cui, Y.; Nies, A. T.; Tsujii, H.; Konig, J. Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family Adv. Enzyme Regul. 2000, 40, 339-49
7. Ogawa, K.; Suzuki, H.; Hirohashi, T.; Ishikawa, T.; Meier, P. J.; Hirose, K.; Akizawa, T.; Yoshioka, M.; Sugiyama, Y. Characterization of inducible nature of MRP3 in rat liver Am. J. Physiol.: Gastrointest. Liver Physiol. 2000, 278 (3) G438-46
8. Hoffman, D. J.; Zanelli, S. A.; Kubin, J.; Mishra, O. P.; Delivoria-Papadopoulos, M. The in vivo effect of bilirubin on the N-methyl-D-aspartate receptor/ion channel complex in the brains of newborn piglets Pediat. Res. 1996, 40 (6) 804-8
9. Ochoa, E. L.; Wennberg, R. P.; An, Y.; Tandon, T.; Takashima, T.; Nguyen, T.; Chui, A. Interactions of bilirubin with isolated presynaptic nerve terminals: functional effects on the uptake and release of neurotransmitters Cell. Mol. Neurobiol. 1993, 13 (1) 69-86
10. Hansen, T. W.; Bratlid, D. Bilirubin and brain toxicity Acta Paediat. Scand. 1986, 75 (4) 513-22
11. Dennery, P. A.; Weng, Y. H.; Stevenson, D. K.; Yang, G. The biology of bilirubin production J. Perinatol. 2001, 21 (Suppl 1) S17-20; discussion S35-9
12. Schwesinger, W. H.; Kurtin, W. E. Changes in serum and bile bilirubin induced by acute hemolysis J. Surg. Res. 1983, 35 (6) 520-4
13. Lathe, G. H. Bilirubin metabolism in haemolytic disease Proc. Roy. Soc. Med. 1955, 48 (4) 271-2
14. Burke, M. D. Liver function: test selection and interpretation of results Clin. Lab. Med. 2002, 22 (2) 377-90
15. Clarke, D. J.; Moghrabi, N.; Monaghan, G.; Cassidy, A.; Boxer, M.; Hume, R.; Burchell, B. Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias Clin. Chim. Acta 1997, 266 (1) 63-74
16. Toh, S.; Wada, M.; Uchiumi, T.; Inokuchi, A.; Makino, Y.; Horie, Y.; Adachi, Y.; Sakisaka, S.; Kuwano, M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome Am. J. Human Genet. 1999, 64 (3) 739-46
17. van de Steeg, E.; Stranecky, V.; Hartmannova, H.; Noskova, L.; Hrebicek, M.; Wagenaar, E.; van Esch, A.; de Waart, D. R.; Oude Elferink, R. P.; Kenworthy, K. E.; Sticova, E.; al-Edreesi, M.; Knisely, A. S.; Kmoch, S.; Jirsa, M.; Schinkel, A. H. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver J. Clin. Invest. 2012, 122 (2) 519-28
18. Strautnieks, S. S.; Bull, L. N.; Knisely, A. S.; Kocoshis, S. A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M. S.; Kagalwalla, A. F.; Nemeth, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N. B.; Gardiner, R. M.; Thompson, R. J. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis Nat. Genet. 1998, 20 (3) 233-8
19. Kullak-Ublick, G. A.; Stieger, B.; Meier, P. J. Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 2004, 126 (1) 322-42
20. Beutler, E. Drug-induced hemolytic anemia Pharmacol. Rev. 1969, 21 (1) 73-103
21. Wright, M. S. Drug-induced hemolytic anemias: increasing complications to therapeutic interventions Clin. Lab. Sci. 1999, 12 (2) 115-8
22. Zalusky, R. Drug-associated hemolytic anemia Bull. New York Acad. Med. 1970, 46 (6) 427-37
23. Zhang, D.; Chando, T. J.; Everett, D. W.; Patten, C. J.; Dehal, S. S.; Humphreys, W. G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Drug Metab. Dispos. 2005, 33 (11) 1729-39
24. Chang, J. H.; Benet, L. Z. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells Mol. Pharmaceutics 2005, 2 (5) 428-34
25. Fisher, M. B.; Campanale, K.; Ackermann, B. L.; VandenBranden, M.; Wrighton, S. A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin Drug Metab. Dispos. 2000, 28 (5) 560-6
26. Chang, J. H.; Yoo, P.; Lee, T.; Klopf, W.; Takao, D. The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe Mol. Pharmaceutics 2009, 6 (4) 1216-27
27. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab. Dispos. 2003, 31 (7) 815-32
28. FDA Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations; Food & Drug Administration: Washington, DC, 2012.
29. Lepine, J.; Bernard, O.; Plante, M.; Tetu, B.; Pelletier, G.; Labrie, F.; Belanger, A.; Guillemette, C. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium J. Clin. Endocrinol. Metab. 2004, 89 (10) 5222-32
30. Zhou, J.; Tracy, T. S.; Remmel, R. P. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors Drug Metab. Dispos. 2011, 39 (2) 322-9
31. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans J. Pharmacol. Exp. Ther. 2004, 311 (1) 139-46
32. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1 Drug Metab. Dispos. 2006, 34 (7) 1229-36
33. Mukerjee, P.; Ostrow, J. D.; Tiribelli, C. Low solubility of unconjugated bilirubin in dimethylsulfoxide-water systems: implications for pKa determinations BMC Biochem. 2002, 3, 17
34. Briz, O.; Serrano, M. A.; MacIas, R. I.; Gonzalez-Gallego, J.; Marin, J. J. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin Biochem. J. 2003, 371 (Pt 3) 897-905
35. Wang, P.; Kim, R. B.; Chowdhury, J. R.; Wolkoff, A. W. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport J. Biol. Chem. 2003, 278 (23) 20695-9
36. Buckley, S. T.; Fischer, S. M.; Fricker, G.; Brandl, M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives Eur. J. Pharm. Sci. 2012, 45 (3) 235-50
37. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-36
38. Tucker, G. T.; Houston, J. B.; Huang, S. M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus Pharm. Res. 2001, 18 (8) 1071-80
39. Ito, K.; Chiba, K.; Horikawa, M.; Ishigami, M.; Mizuno, N.; Aoki, J.; Gotoh, Y.; Iwatsubo, T.; Kanamitsu, S.; Kato, M.; Kawahara, I.; Niinuma, K.; Nishino, A.; Sato, N.; Tsukamoto, Y.; Ueda, K.; Itoh, T.; Sugiyama, Y. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 2002, 4 (4) E25
40. Blanchard, N.; Richert, L.; Coassolo, P.; Lave, T. Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration Curr. Drug Metab. 2004, 5 (2) 147-56
41. REYATAZ; Bristol-Myers Squibb: Princeton, NJ, 2012, [package insert].
42. CRIXIVAN; Merck and Co., Inc.: Whitehouse Station, NJ, 2012, [package insert].
43. NORVIR; Abbott Laboratories: North Chicago, IL, 2012, [package insert].
44. VIRACEPT; Agouron Pharmaceuticals, Inc.: La Jolla, CA, 2001, [package insert].
45. Campbell, S. D.; de Morais, S. M.; Xu, J. J. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia Chemico-biol. Interact. 2004, 150 (2) 179-87
46. Annaert, P.; Ye, Z. W.; Stieger, B.; Augustijns, P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1 Xenobiotica 2010, 40 (3) 163-76
47. Tucker, G. T. The rational selection of drug interaction studies: implications of recent advances in drug metabolism Int. J. Clin. Pharmacol., Ther., Toxicol. 1992, 30 (11) 550-3
48. Lankisch, T. O.; Moebius, U.; Wehmeier, M.; Behrens, G.; Manns, M. P.; Schmidt, R. E.; Strassburg, C. P. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype Hepatology 2006, 44 (5) 1324-32
49. Lankisch, T. O.; Behrens, G.; Ehmer, U.; Mobius, U.; Rockstroh, J.; Wehmeier, M.; Kalthoff, S.; Freiberg, N.; Manns, M. P.; Schmidt, R. E.; Strassburg, C. P. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - an extended haplotype of genetic variants increases risk in indinavir treatment J. Hepatol. 2009, 50 (5) 1010-8
50. Hu, M.; Tomlinson, B. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia Atherosclerosis 2012, 223 (2) 427-32
51. Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P. J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions Clin. Pharmacol. Ther. 2001, 69 (4) 223-31
52. Fontana, R. J.; McCashland, T. M.; Benner, K. G.; Appelman, H. D.; Gunartanam, N. T.; Wisecarver, J. L.; Rabkin, J. M.; Lee, W. M. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group Liver Transplant. Surg. 1999, 5 (6) 480-4
53. Skjodt, N. M.; Davies, N. M. Clinical pharmacokinetics and pharmacodynamics of bromfenac Clin. Pharmacokinet. 1999, 36 (6) 399-408
54. Graham, D. J.; Green, L.; Senior, J. R.; Nourjah, P. Troglitazone-induced liver failure: a case study Am. J. Med. 2003, 114 (4) 299-306
55. REZULIN; Parke Davis Pharmaceuticals, Ltd.: Vega Baja, PR, 1999, [package insert].
56. Lazarczyk, D. A.; Goldstein, N. S.; Gordon, S. C. Trovafloxacin hepatotoxicity Digest. Dis. Sci. 2001, 46 (4) 925-6
57. TROVAN; Pfizer Inc.: New York, NY, 2000, [package insert].
58. Uglietti, A.; Novati, S.; Gulminetti, R.; Maserati, R. Correlations between atazanavir C(trough)and hyperbilirubinemia: a case report J. Med. Case Rep. 2009, 3, 9307
59. Loi, C. M.; Alvey, C. W.; Vassos, A. B.; Randinitis, E. J.; Sedman, A. J.; Koup, J. R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites J. Clin. Pharmacol. 1999, 39 (9) 920-6
60. Teng, R.; Liston, T. E.; Harris, S. C. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers J. Antimicrob. Chemother. 1996, 37 (5) 955-63